Literature DB >> 25142448

Improving DNA vaccine performance through vector design.

James A Williams1.   

Abstract

DNA vaccines are a rapidly deployed next generation vaccination platform for treatment of human and animal disease. DNA delivery devices, such as electroporation and needle free jet injectors, are used to increase gene transfer. This results in higher antigen expression which correlates with improved humoral and cellular immunity in humans and animals. This review highlights recent vector and transgene design innovations that improve DNA vaccine performance. These new vectors improve antigen expression, increase plasmid manufacturing yield and quality in bioreactors, and eliminate antibiotic selection and other potential safety issues. A flowchart for designing synthetic antigen transgenes, combining antigen targeting, codon-optimization and bioinformatics, is presented. Application of improved vectors, of antibiotic free plasmid production, and cost effective manufacturing technologies will be critical to ensure safety, efficacy, and economically viable manufacturing of DNA vaccines currently under development for infectious disease, cancer, autoimmunity, immunotolerance and allergy indications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25142448     DOI: 10.2174/156652321403140819122538

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  29 in total

1.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

Review 2.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

3.  Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.

Authors:  Zahra Heidari; Jaspreet S Arora; Dibyadyuti Datta; Vijay T John; Nirbhay Kumar; Geetha P Bansal
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

4.  Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.

Authors:  Xia Jin; Cecilia Morgan; Xuesong Yu; Stephen DeRosa; Georgia D Tomaras; David C Montefiori; James Kublin; Larry Corey; Michael C Keefer
Journal:  Vaccine       Date:  2015-03-25       Impact factor: 3.641

Review 5.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

6.  Generation of High-Specificity Antibodies against Membrane Proteins Using DNA-Gold Micronanoplexes for Gene Gun Immunization.

Authors:  Debra T Hansen; Felicia M Craciunescu; Petra Fromme; Stephen A Johnston; Kathryn F Sykes
Journal:  Curr Protoc Protein Sci       Date:  2018-02-21

Review 7.  Antibiotic-free selection in biotherapeutics: now and forever.

Authors:  Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Pathogens       Date:  2015-04-03

Review 8.  Oxidative stress implications for therapeutic vaccine development against Chagas disease.

Authors:  Subhadip Choudhuri; Lizette Rios; Juan Carlos Vázquez-Chagoyán; Nisha Jain Garg
Journal:  Expert Rev Vaccines       Date:  2021-08-30       Impact factor: 5.217

9.  Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.

Authors:  Lichen Jing; Mariliis Ott; Candice D Church; Rima M Kulikauskas; Dafina Ibrani; Jayasri G Iyer; Olga K Afanasiev; Aric Colunga; Maclean M Cook; Hong Xie; Alexander L Greninger; Kelly G Paulson; Aude G Chapuis; Shailender Bhatia; Paul Nghiem; David M Koelle
Journal:  Cancer Immunol Res       Date:  2020-03-16       Impact factor: 11.151

Review 10.  Molecular mechanisms for enhanced DNA vaccine immunogenicity.

Authors:  Lei Li; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2015-12-28       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.